# IRCCS Humanitas Research Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/irccs-humanitas-research-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 74 |
| Citations | 993,669 |
| City | Rozzano |
| Country | IT |
| Description | IRCCS Humanitas Research Hospital is a research organisation in Rozzano, IT. OpenAlex records 16,898 works and 993,669 citations for it. 4,269 researchers list it as their most recent affiliation. |
| Homepage | http://www.humanitas.it/en |
| OpenAlex ID | https://openalex.org/I4210163047 |
| Researchers | 4,269 |
| ROR ID | https://ror.org/05d538656 |
| Type | healthcare |
| Works | 16,898 |

## University papers

- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer](https://scholariq.org/papers/redistribution-hyperproliferation-activation-of-natural-killer-cells-and-cd8-t/)
- [Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial](https://scholariq.org/papers/lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer/)
- [Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial](https://scholariq.org/papers/activity-and-safety-of-ceritinib-in-patients-with-alk-rearranged-non-small-cell/)
- [ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy](https://scholariq.org/papers/esc-guidelines-on-the-management-of-cardiovascular-diseases-during-pregnancy/)
- [Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-anti-pd-1-antibody-pembrolizumab-in/)
- [Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation](https://scholariq.org/papers/clinical-effects-of-driver-somatic-mutations-on-the-outcomes-of-patients-with/)
- [Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy](https://scholariq.org/papers/phase-ii-study-of-everolimus-in-patients-with-thymoma-and-thymic-carcinoma/)

## University top topics

Showing 8 of 25.

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.